Introduction
Acute ischemic stroke is a major cause of death and, even when not fatal, usually results in permanent neurological impairments, for which both blood flow improvement and neuroprotective therapies are critical. A thrombolytic agent, tissue plasminogen activator (tPA), has been used for the treatment of acute cerebral infarction, but its application is limited due to the narrow therapeutic time window and side effect of hemorrhagic transformation (Tsirka et al., 1995; Wang et al., 1998; Nagai et al., 1999; Ning et al., 2006; Yamashita et al., 2009; Abu et al., 2010) . Intravenous tPA treatment has been limited to within 3 hrs after the onset of ischemic stroke, but recent clinical evidence provided an extension of the time window from 3 to 4.5 hrs (Wahlgren et al., 2008; Lansberg et al., 2009 ). However, the extension also increased the risk of hemorrhagic complications (Wahlgren et al., 2008; Lansberg et al., 2009) , which further increases the demand for neuroprotection to reduce the risk of harmful cerebral hemorrhage.
The generation of reactive oxygen species (ROS) starts soon after vessel occlusion and propagates explosively after reperfusion (Chan, 2001 ). These ROS have been proved to be of key importance in the pathogenesis of ischemic brain injury (Kinouchi et al., 1991; Kontos, 2001 ).
We originally reported that a free radical scavenger edaravone strongly ameliorated edema in the ischemic brain (Abe et al., 1988) and reduced the infarct size and free radical end products of lipids, proteins, and DNA (Zhang et al., 2004) . Because edaravone strongly improved the 6 disability after ischemic stroke without serious adverse events (The Edaravone Acute Brain Infarction Study group, 2003) , it has been used in clinical therapy for ischemic stroke in Japan from 2001. We have furthermore reported the strong neuroprotective effect of edaravone especially in preserving neurovascular units (NVU) after cerebral ischemia in the stroke-prone spontaneously hypertensive rat (Yamashita et al., 2009) . Besides edaravone, we have also reported that ischemic brain damage was ameliorated by other neuroprotective substrates such as HMG-CoA reductase inhibitor statins (Hayashi et al., 2005; Nagotani et al., 2005) , antihypertensive azelnidipine (Lukic-Panin et al., 2007) , and biliverdin (Deguchi et al., 2008) after ischemic stroke.
Platinum nanoparticle (nPt) species have been reported as novel free radical scavengers which strongly ameliorate oxidative damage in vitro and in vivo (Kim et al., 2008 Onizawa et al., 2009; Watanabe et al., 2009; Sakaue et al., 2010; Takamiya et al., 2011) . Due to the larger surface area-to-volume ratio of smaller particles, nPt can potentiate the catalytic activity of metals, and its colloidal forms contribute to a further efficient catalysis with high electron holding at the surface (Roucoux et al., 2002) , allowing it to quench both superoxide anion and hydrogen peroxide (Kajita et al., 2007; Hamasaki et al., 2008) . We have previously reported that administration of nPt could be beneficial for clinical improvement and neuroprotection in the pathological aspects of mice after transient middle cerebral artery occlusion (tMCAO) (Takamiya et al., 2011) , and in the present study, we further investigated the efficacy of nPt associated with tPA administration. were anesthetized with an nitrousoxide/oxygen/isofluran mixture (69: 30: 1%) during surgical preparation. tMCAO was induced by the intraluminal filament technique according to our previous report (Lukic-Panin et al., 2007; Abe et al., 1992; Yamashita et al., 2006) . In brief, the right common carotid artery was isolated and a small incision was made for thread insertion.
Then, 8-0 nylon thread with a silicon-coated tip was inserted into the right MCA and gently advanced 9.0-10.0 mm to occlude the origin of MCA. During these surgical treatments and subsequent ischemic period, body temperature was monitored to maintain a temperature of 37 ± 0.3°C by placing animals on a heating bed (Model BWT-100; Bio Research Center, Nagoya, Japan). Regional CBF in the ischemic area was estimated by measuring blood flow at partial resection of the scalp 1 mm posterior and 3 mm lateral to the bregma with a laser-Doppler flow meter (FLO-C1; Omegawave, Tokyo, Japan). CBF was monitored at a baseline time point before the ischemic operation, at 5 and 10 min after the cerebral ischemia, and at 5 min after the reperfusion, as described in our previous reports (Lukic-Panin et al., 2007; Yamashita et al., 2006) . At 60 min after tMCAO, the nylon thread was withdrawn for reperfusion, followed by intravenous administration of the drug as described below in detail. After the incision was closed, the animals recovered and were allowed free access to water and food at an ambient temperature (21-23°C) until motor function evaluation, in vivo imaging, and subsequent brain sampling for 8 ex vivo imaging, infarction volume determination, zymography, and immunohistochemistry. The experimental protocol and procedure were approved by the Animal Committee of the Graduate School of Medicine and Dentistry, Okayama University.
Preparation and administration of drug and 5 mice groups
The nPts were prepared by ethanol reduction of H 2 PtCl 6 ・ 6H2O as described previously (Kim et al., 2008) . Poly (N-vinyl-2-pyrrolidone) was used as a protecting reagent to prepare an evenly dispersed suspension. The nPts were dissolved in physiological saline (PS) and stored at 4°C until use.
The mice were divided into 5 groups, the sham control group receiving only a surgical sham operation without thread insertion (total n=12: 3 for motor function assessment with subsequent infarction volume determination and immunohistochemistry, 3 for in vivo and ex vivo optical imaging of MMP, 3 for zymography, and 3 for detection of superoxide anion), the tMCAO-vehicle group receiving only a vehicle (PS administered from tail vein at 10 mL/kg of mouse) at the time of reperfusion after 60 min of tMCAO (total n=21: 12, 3, 3, and 3), the tMCAO-tPA (Alteplase, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, intravenously, 10mg/kg) group receiving tPA at reperfusion (total n=17: 8, 3, 3, and 3), tMCAO-tPA+nPt group receiving nPts (4.0 μmol/kg of mouse) just after tPA administration at reperfusion (total n=17: 8, 3, 3, and 3), and tMCAO-nPt group receiving nPts at reperfusion (total n=19: 10, 3, 3, and 3).
The administration volume of each group was approximately 0.3 ml according to the weight of 9 the mice.
Behavioral analysis
At 48 hrs after the reperfusion, the mice were evaluated by behavioral tests as described by Bederson (Bederson et al., 1986) with our minor modifications (Yamashita et al., 2009) as follows: 0, no observable neurologic deficits; 1, failure to extend the right forepaw; 2, circling to the contralateral side; 3, falling to the right; 4, unable to walk spontaneously. After Bederson's test, a rota-rod test (MK-610A, MUROMACHI KIKAI CO., LTD) was performed 3 times with an accelerating spindle speed from 5 to 45 rpm over a period of 1 min. The scoring was carried out blind to each condition.
Measurement of infarct volume
After finishing behavioral analysis, the mice were anesthetized again by intraperitoneal injection of pentobarbital (40 mg/kg), and transcardially perfused with chilled 5 U/ml heparin in phosphate-bufferd saline (PBS), followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Subsequently, brains were removed, immersed with 4% paraformaldehyde in PBS over night at 4,°C and subjected to consecutive incubation with 10, 20 and 30% sucrose in PBS. Each sucrose incubation step was for 24 hrs at 4°C. Then, the treated brains were rapidly frozen in dry ice for preparation of 20 μm thick coronal sections at the caudate level with a cryostat maintained at -20°C. The sliced sections were mounted on silane-coated slide glasses.
10 Coronal brain sections of these mice were stained with HE to quantify infarct volume with a standard computer-assisted image analysis technique. The total infarct volume of the cerebral cortex or CPu for each brain was calculated by summation of the infarcted area of 7 serial brain slices, at a 500 μm interval each, between 1.0 mm anterior, and 2.0 mm posterior, to the bregma.
To eliminate the contribution of postischemic edema, infarct volume measurements were corrected as previously described (Kitano et al., 2004) .
In vivo optical imaging of matrix metalloproteinase
Mice were subjected to in vivo imaging at 48 hrs after the tMCAO. The fluorescent compound MMPSense 680 (VisEn Medical Inc., USA) was used in this experiment for testing matrix metalloproteinases (MMPs including MMP-2, -3, the key -9 and -13). MMPSense (300 μl) was intravenously injected 12 hrs before the in vivo imaging (i.e., 36 h after tMCAO). For in vivo imaging, the mice were anesthetized with a nitrous oxide/oxygen/isoflurane mixture (69/30/1%) administered through an inhalation mask, and the near-infrared fluorescence (NIRF) images were observed by a macro fluorescence imaging system as described above with or without the head skin.
For in vivo imaging, we used the macro fluorescence imaging system MVX 10 Macro View (Olympus, Japan). For excitation of fluorescent compounds, an intensity-controlled laser diode emitting at 682 nm was used. The fluorescence emission at 721 nm was collected by a 11 charge-coupled device (CCD) camera (Digital camera C10600 ORCA-R2, Hamamatsu, Japan) with an acquisition time of 3.0 sec. The transillumination fluorescence images (TFI) were analyzed by MetaMorph Version 7.5 image analysis software.
Ex vivo optical imaging of matrix metalloproteinase
After taking in vivo images, the mouse brains were removed under deep anesthesia with pentobarbital (40 mg/kg, i.p.), and ex vivo imaging for MMP was quickly performed as above.
Just after ex vivo imaging of the tMCAO-tPA-treated mouse brains, immunofluorescent staining of MMP-9 was performed with the primary antibody for MMP-9 (1:200; R&D SYSTEMS, Minnesota) and secondary antibody conjugated with Alexa Fluor 488 (1:500; Invitrogen, CA) to confirm that the fluorescence actually represents MMP. Using another set of tMCAO-tPA treated mice (n=3), TTC stain was also performed after obtaining ex vivo images with MMPSense.
Immunohistochemistry
As described above, coronal brain sections of 20 μm thickness at the caudate level were cut and mounted on silane-coated slide glasses. The sections were first washed in PBS and then incubated with 30% methanol and 0.3% hydrogen peroxide in PBS in order to quench endogenous peroxide activity. After non-specific reactions were blocked by 5% bovine serum 12 albumin (BSA) in PBS for 1 hr, the slides were incubated overnight at 4°C with the primary antibody in 5% BSA in PBS. Then, the slides were washed in PBS and incubated for 1 hr with an appropriate biotin-labeled secondary antibody (1:500) at room temperature. They were subsequently incubated with an avidin-biotin-peroxide complex (Vector Laboratories, Burlingame, CA) for 30 min and the signal was visualized with diaminobenzidine tetrahydrochloride. The primary antibodies in this study were as follows: anti-MMP-9 (1:200; R&D SYSTEMS, Minnesota), anti-collagen IV (1:100; NOVOTEC, Lyon, France), anti-occludin (1:100; SANTA CRUZ Biotechnology, CA), and NAGO (1:200; Vector Laboratories, Burlingame, CA). In each study, sections were stained in a similar way without the primary antibody as a negative control.
Gelatine zymography
At 48 hrs after reperfusion, mice were anesthetized by intraperitoneal injection of pentobarbital (40 mg/kg) and transcardially perfused with chilled 5 U/ml heparin in PBS. Brains were removed quickly and divided into ipsilateral-ischemic and contralateral-nonischemic hemispheres. Each hemispheric brain was frozen immediately in dry ice and stored at -80°C until use.
Brain samples were homogenized in a 10 × volume lysis buffer (150 mM NaCl, 1% SDS, 0.1% deoxycholic acid, and 50 mM Tris-HCl, pH 7.4) containing protease inhibitors. After centrifugation at 9,000 × g for 15 min at 4°C, the supernatant was collected. The total protein 13 concentration of each supernatant sample was spectrophotometrically determined using the Bradford assay (Ultrospec 3100 pro, GE Healthcare, Tokyo, Japan). The MMP-9 activity of each sample was measured using a gelatin-zymography kit (Primary cell, Sapporo, Japan) according to the manufacturer's instructions. In brief, each sample containing 20 μg protein was diluted with the homogenizing buffer in the kit, mixed with an equal volume of sample buffer, and loaded for the electrophoresis for 2 hrs. The gels were washed and incubated for 24 hrs with the incubation buffer at 37°C. The gels were stained with Coomassie blue and scanned. Quantitative densitometric analysis was performed using ImageJ software.
Detection of superoxide anions (SA) and double immunofluorescent analysis
Production of SA in the mouse brains after 60 min of tMCAO was investigated by in situ detection with oxidized hydroethidine (HEt) as described previously (Sugawara et al., 2002) .
Intravenously-administered HEt (Molecular Probes, Eugene, OR) is taken up by living cells and oxidized by SA to produce a red fluorescent dye, ethidium (Bindokas et al., 1996) . In the present experiment, 0.1 ml of 1 mg/ml HEt in PS containing 1% dimethylsulfoxide was administered via the tail vein at 60 min after tMCAO. At 60 min after the drug administration, mice were anesthetized by intraperitoneal injection of pentobarbital (40 mg/kg) and transcardially perfused with chilled 5 U/ml heparin in PBS, followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were then removed, immersed with 4% paraformaldehyde in PBS overnight at 4°C, and rapidly frozen in dry ice. Twenty micrometer thick coronal sections were 14 cut at the caudate level with a cryostat kept at -20°C and mounted on silane-coated slide glasses.
Immunofluorescent analysis was performed to investigate the ROS-production level of each cell component constituting brain tissue. The sections were first washed in PBS and after non-specific reactions were blocked by 5% BSA in PBS for 1 hr, the slides were incubated overnight at 4°C with the primary antibody in 5% BSA in PBS. The slides were then washed in First semiquantitative fluorescence were measured in the anatomically comparable sites of 15 contralateral hemisphere with the peri-infarct region of ipsilateral hemisphere by calculating the sum of integral intensity using the image analysis software, then we confirmed that there were no significant difference in the fluorescent signal intensity between sham control and each tMCAO groups. Subsequently integral fluorescent signal intensity of contralateral site comparable to peri-infarct region of ipsilateral hemisphere were hence subtracted to correct for background.
Statistical analysis
Results are presented as the mean ± standard deviation (SD). Statistical comparisons were conducted using Mann-Whitney tests followed by Kruskal-Wallis tests for intergroup comparisons. A probability value of p < 0.05 was considered statistically significant. 
Cerebral blood flow (CBF)
After tMCAO, CBF immediately dropped to less than 30% of the baseline. With reperfusion, CBF quickly recovered to the basal level in all groups (i.e. tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt and tMCAO-nPt groups). Throughout these tMCAO experiments, there was no significant difference in CBF between all groups (data not shown).
Motor function and infarct volume
To evaluate motor function in the mice at 48 hrs after 60 min of tMCAO, Bederson's and rota-rod tests were performed. Bederson's grades of the sham control, tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt groups were 0 ± 0 (mean ± standard deviation), 2.17 ± 0.39 ⋆⋆ , 2.38 ± 0.52 ⋆⋆ , 1.63 ± 0.52 ⋆⋆, * ,# and 1.10 ± 0.57 ⋆⋆, **, respectively (⋆⋆p < 0.01 vs sham control group, *p < 0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group; Fig. 1A ). Rota-rod scores of the above 5 groups were 44.3 ± 15.3 (sec), 17.3 ± 5.4 ⋆⋆ , 11.9 ± 3.8 ⋆⋆, *, 21.7 ± 8.5 ⋆⋆,# , and 29.9 ± 9.0 , **, respectively (⋆⋆p < 0.01 vs sham control group, *p < 0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group; Fig. 1B ).
Hematoxyline-eosin (HE) -stained sections at 48 hrs after 60 min of tMCAO showed that the infarct volumes at the cerebral cortex in the tMCAO-vehicle and -nPt groups were 30.1 ± 5.2 (mm 3 ), 38.2 ± 5.7**, 22.1 ± 6.3* ,## , and 17.3 ± 6.8** (*p < 0.05, **p < 0.01 vs tMCAO-vehicle group, ##p < 0.01 vs MCAO-tPA group), and at the caudoputamen (CPu) were 9.2 ± 1.3, 9.2 ± 17 0.9, 7.5 ± 1.5* ,# and 7.3 ± 1.2** (p = n.s.), respectively (*p < 0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs MCAO-tPA group) (Fig. 1C) .
In vivo and ex vivo optical imaging of matrix metalloproteinase
The in vivo fluorescent optical signal of matrix metalloproteinase (MMP) was scarcely detected with scalp and hair, but became clearly detected through skull bone by removing the scalp. Fig. 2A demonstrates the in vivo optical image of MMP at 48 hrs after tMCAO by near-infrared fluorescence (NIRF) observation of fluorescent compounds using MMPSense 680
(upper panels for non-fluorescence observation, and the lower panels for pseudocolor image).
There was almost no fluorescence over the sham control head, but clear fluorescence was observed in the affected hemisphere reflecting the right middle cerebral artery (MCA) territory, with signal strength in the order tMCAO-tPA > tMCAO-vehicle > tMCAO-tPA+nPt > tMCAO-nPt group ( Fig. 2A ; lower panels). Fig. 2A) , the fluorescent signal became more evident in the affected right MCA territory, with signal strength again in the order tMCAO-tPA > tMCAO-vehicle > tMCAO-tPA+nPt > tMCAO-nPt group ( Fig. 2B and 2C ; lower panels).
Macroscopic comparison of brain sections with TTC stain and ex vivo MMP images in 18 identical tMCAO-tPA mice showed close colocalization of 2,3,5-triphenyltetrazolium chloride (TTC) stain defect (white area, Fig. 2D ) and MMP image increase (yellow area, Fig. 2D ).
Microscopic examination confirmed the colocalization of endogenous MMPSense signal and exogenous MMP-9 antibody in the affected area (Fig. 2E) .
Zymography for MMP-9 activity
There was only a trace level of MMP-9 activity in the sham control and contralateral brains of the tMCAO groups, which showed an evident increase in the ipsilateral hemisphere after tMCAO (Fig. 3A) . As the reference of this sham control activity 1.00, relative ratio (RR) of the optical densities for MMP-9 in tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt in the contralateral hemisphere as 1.16 ± 0.40, 1.82 ± 1.01, 0.99 ± 1.00, and 1.20 ± (Fig. 3B) .
Immunohistochemistry for NVU
Staining for NAGO exhibited short linear structures with a few branches in the peri-infarct area of cerebral cortex, representing the vascular endothelium (Fig. 4, top Staining for occludin also showed small linear structures with a few branches, representing the tight junction of neurovascular components (Fig. 4, second panels) . The RR of signal intensities for occludin staining in these 5 groups were 1.00 ± 0.06, 0.72 ± 0.32 ⋆⋆ , 0.70 ± 0.19 ⋆⋆ , 0.81 ± 0.29, and 0.86 ± 0.31, respectively (⋆⋆p < 0.01 vs sham control group). The signal intensity tended to be lower in the tMCAO-vehicle and tMCAO-tPA group, but again no significant difference was found.
Staining for collagen IV also showed linear structures with a few branches, clearly representing the basal lamina of neurovascular components (Fig. 4, third panels) . The RR of signal intensities of collagen IV of the sham control, tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.00 ± 0.08, 0.58 ± 0.32 ⋆⋆ , 0.30 ± 0.27 ⋆⋆ , 0.74 ± 0.23 ⋆,## , and 0.85 ± 0.14 ⋆, * (⋆p < 0.05, ⋆⋆p < 0.01 vs sham control group, *p < 0.05 vs tMCAO-vehicle group, ##p < 0.05 vs tMCAO-tPA group), respectively. Collagen IV was significantly degraded at 48 hrs after 60 min of tMCAO, which tended to be exacerbated by tPA administration, and these degradation were significantly salvaged by the nPt-treatment.
Staining for MMP-9 showed several shapes such as a similar linear structure to NAGO, occludin and collagen IV, and its surrounding small dots (Fig. 4, bottom panels) , representing the extracellular matrix and possibly cells generating MMP-9 in the peri-infarct area. The RR of signal intensities for the MMP-9 of the sham control, tMCAO-vehicle, tMCAO-tPA, 20 tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.00 ± 0.24, 5. ** (⋆⋆p < 0.01 vs sham control group, *p < 0.05, **p < 0.01 vs tMCAO-vehicle group, ##p < 0.01 vs tMCAO-tPA group), respectively. MMP-9 staining was markedly increased at 48 hrs after tMCAO, which was exacerbated by tPA administration, and these marked increase were significantly inhibited by the nPt-treatment.
In all immunostainings above, no significant staining was found without a primary antibody, supporting the specific staining for each marker protein.
Evaluation of superoxide production
Although no signal was detected in the sham control brain, the tMCAO-vehicle and tMCAO-tPA groups showed strong signals at the peri-infarct area in the ipsilateral cerebral cortex of the MCA territory. This signal was markedly reduced in the tMCAO-tPA+nPt and tMCAO-nPt groups (Fig. 5A ). Statistical analysis of these signals showed that the RR of the signal intensities for superoxide of the sham control, tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.0 ± 0.4, 14.0 ± 6.6 ⋆⋆ , 37.5 ± 12.2 ⋆⋆, **, 6.5 ± 1.5 ⋆,# , and 2.6 ± 0.2 ⋆, *, respectively (⋆p < 0.05, ⋆⋆p < 0.01 vs sham control group, *p < 0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group; Fig. 5A ). Triple immunofluorescent analysis showed hydroethidine signals indicating the existence of superoxide predominantly in the endothelium (Fig. 5B, filled arrows) and at the peri-infarct area in the ipsilateral cerebral cortex of the MCA territory of tMCAO-vehicle and tMCAO-tPA groups with 21 less intensity with nPt treatments (Fig. 5B, open arrows) . Small numbers of hydroethidine signals were also present in the outer margin of MAP2 fluorescence, suggesting a slight ROS production in the cytoplasmic membrane of peri-infarct neurons. The ROS production ratios of each cell component were as follows; the ratios of endothelium, neuron, microglia, and astrocyte were 95.1%, 2.0%, 2.9% and 0%, respectively in sham control group, 44.6%, 39.4%, 12.7%, and 3.2%
in tMCAO-vehicle group, 53.1%, 36.5%, 6.1%, and 4.1% in tMCAO-tPA group, 79.2%, 14.1%, 1.7%, and 5.0% in tMCAO-tPA+nPt group, 94.1%, 2.0%, 2.8%, and 1.1% in tMCAO-nPt group, respectively (Fig. 5A ).
Discussion
The generation of ROS gradually increases during cerebral ischemia, but explosively increases after reperfusion especially in the ischemic penumbra oxidising the lipid, DNA and proteins (Chan, 1996; Morimoto et al., 1996; Peters et al., 1998; Abe, 2000; Cui et al., 2000; Zhang et al., 2001) . Thus the detrimental effects of ROS in cerebral ischemia-reperfusion injury are profoundly associated with the pathophysiology of neural cell apoptosis and necrotic infarction (Demopoulos, 1973; Hayashi et al., 1999) . We have previously demonstrated the strong neuroprotective effects of a free radical scavenger edaravone (Yamashita et al., 2009; Abe et al., 1988; Yoneda et al., 2003) , which has been clinically used as the world's first neuroprotective drug in Japan since 2001. Recent evidence suggested that other free radical scavengers such as biliverdin (Deguchi et al., 2008), 6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxylic acid (trolox) (Perfeito et al., 2007; Sharma and Kaundal, 2007) and 2,2,5,7,8-pentamethyl-6-hydroxychromane (PMC) (Hsiao et al., 2007) also ameliorated cerebral injury following experimental tMCAO.
In the present study, we took a novel free radical scavenger nPts because of its double-scavenging property for superoxide anion and hydrogen peroxide. The size of nPt, ranging from 2-3 nm, is the most potent subclass of antioxidant for application in living bodies.
Unlike common antioxidants such as ascorbic acid which lose their reduction effect when oxidized, the antioxidative effect of nPt is durable for its feature as both SOD/catalase mimetic (Kajita et al., 2007; Hamasaki et al., 2008) . In in vivo application, nPt extended the lifespan of 23 the roundworm Caenorhabditis ekegans (Kim et al., 2008 Sakaue et al., 2010) , inhibited pulmonary inflammation in mice exposed to cigarette smoke (Onizawa et al., 2009) , and inhibited cell growth of human tongue carcinoma cells (Saitoh et al., 2009 ). Furthermore we have previously reported that nPt ameliorates neurological function and brain damage after tMCAO in mice (Takamiya et al., 2011) . The present study confirmed these findings and additionally showed that nPt ameliorated the exacerbated damage caused by tPA in conjunction with tMCAO in mice.
Large quantities of ROS are generated in the peri-vascular extracellular space after cerebral ischemia (Kontos et al., 1992) . Such ROS are important for MMP-9 activation which participates in early blood-brain barrier (BBB) disruption triggered by oxidative stress generated during cerebral ischemia-reperfusion injury (Gasche et al., 2001; Kamada et al., 2007) . Several experiments have demonstrated that early inhibition of MMP-9 significantly reduces the brain infarct size, indicating that MMP-9 is an important enzyme in contributing to focal ischemic brain injury (Yong et al., 2001; Tsuji et al., 2005 , Klohs et al., 2009 Yagi et al., 2009 ). We previously reported that the free radical scavenger edaravone shows a protective effect on the NVU reducing MMP-9 activation after tMCAO of rats (Yamashita et al., 2009) . Intravenous or intracerebral administration of tPA upregulates MMP-9 and exacerbates cerebral infarction through low-density lipoprotein receptor-related protein (Wang et al., 2003; Tsuji et al., 2005; Machado et al., 2009; Yagi et al., 2009; Fanne et al., 2010; Lukic-Panin et al., 2010) . The present study demonstrated that administration of tPA at the time of reperfusion 24 significantly deteriorated the motor function of mice and increased infarct volume especially in the cerebral cortex, and that such clinical and pathological damage by tPA was significantly prevented by administration of nPt (Fig. 1) . We further demonstrated that in vivo imaging of MMP activity was well correlated with MMP-9 activity and destruction of NVU after tMCAO, which was also ameliorated by nPt (Fig. 2-4) . In the present study, the inner components of NVU such as NAGO and occludin were slightly damaged after tMCAO and administration of tPA as compared to stronger damage in the outer component collagen IV (Fig. 4) , similar to our previous report (Yamashita et al., 2009) . In the present study the site of ROS production after tMCAO and tPA administration was mainly the cerebrovascular endothelium and neurons, with a few in microglia and astrocytes (Fig. 5a ). Both this ROS production and the preferential disruption of NVU were reduced by the present nPt treatment (Fig. 2-5 ), suggesting that nPt is a potential therapeutic option for ischemic stroke. The present study thus provides evidence for the therapeutic potential of new nPt with both SOD and catalase mimic activities for ischemic stroke patients with NVU protection to improve motor functions through strong antioxidative mechanisms.
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